Abstract
The complexity of the treatment of herpetic keratoconjunctivitis is due to the severity of the disease, complications, the transition to chronic relapsing forms and the insufficient effectiveness of the drugs used, which leads to a steady increase in the number of patients. The aim of the study was to evaluate the therapeutic efficacy of the eye drug films «GlazAvir» in the experimental model of acute herpetic eye infection in rabbits. to study the specific activity of «GlazAvir» and compare the long-term indicators of the level of manifestation of individual clinical signs of keratoconjunctivitis. In the work we used rabbits of the Chinchilla breed, the herpes simplex virus type 1 and the eye drug films «GlazAvir». A model of ophthalmic herpetic infection was formed by infection of rabbits with virus-containing material of a pre-scarified eye cornea against the background of local anesthesia. Аnimals were treated with the drug «GlazAvir» - 1 application per day for 7 days. Animals were observed daily for 15 days, then every 3 days until the 25th day of observation. The effectiveness of the drug was evaluated at the peak of the development of the pathological process. There was a decrease in mortality from 50 to 20%, and an increase in average life expectancy by 27.87%, compared with the control in animals treated with «GlazAvir». It was noted after activation of herpetic keratoconjunctivitis on the 2nd - 5th day, at the peak of the disease (6-9th day) a statistically significant decrease in the activity of the pathological process (p<0.05) by rabbits treated with the «GlazAvir» ophthalmic drug films. The tendency to normalization by the rabbits treated with the «GlazAvir» preparation was observed until the 14th day. The data obtained indicate the pronounced effectiveness of the «GlazAvir» preparation in the treatment of experimental herpesvirus keratoconjunctivitis.
Highlights
The complexity of the treatment of herpetic keratoconjunctivitis is due to the severity of the disease, complications, the transition to chronic relapsing forms and the insufficient effectiveness of the drugs used, which leads to a steady increase in the number of patients
The aim of the study was to evaluate the therapeutic efficacy of the eye drug films «GlazAvir» in the experimental model of acute herpetic eye infection in rabbits
A model of ophthalmic herpetic infection was formed by infection of rabbits with virus-containing material of a pre-scarified eye cornea against the background of local anesthesia
Summary
Иванова А.М.1, Имомалиева К.М.2, Наровлянский А.Н.1, Изместьева А.В.1, Сарымсаков А.А.3, Билалов Э.Н.2, Ершов Ф.И.1. Цель исследования – оценка терапевтической эффективности глазных лекарственных плёнок «ГлазАвир» в экспериментальной модели острой герпетической инфекции глаз у кроликов. В работе использовали кроликов породы «Шиншилла», вирус герпеса простого 1-го типа и глазные лекарственные плёнки «ГлазАвир». Лечили животных препаратом «ГлазАвир» – 1 аппликация в день в течение 7 дней. У кроликов, получавших лечение глазными лекарственными плёнками «ГлазАвир», после активизации герпетического кератоконъюктивита на 2–5-й день, на пике развития заболевания (6–9-й день) отмечено статистически достоверное снижение активности патологического процесса (p < 0,05). Тенденция к нормализации состояния у леченных препаратом «ГлазАвир» кроликов прослеживалась до 14-го дня наблюдения. Полученные данные свидетельствуют о выраженной эффективности препарата «ГлазАвир» при лечении экспериментального герпесвирусного кератоконъюнктивита. Глазные лекарственные плёнки в лечении экспериментального герпетического кератоконъюнктивита. Ophthalmic drug films in the therapy of experimental herpetic keratoconjunctivitis
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
